Treating BRCA breast cancer with PARP inhibition

Phase III results of olaparib for BRCA breast cancer

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy

Olaparib slows growth of BRCA-related metastatic breast cancer

No link between pregnancy and breast cancer relapse

Pregnancy after breast cancer no associated with relapse risk

Functions of BRCA1 and the implications for treatment

Genetic determinants of breast cancer immune phenotypes

IMPAKT conference highlights

Mutational landscapes in pregnant and non-pregnant breast cancer

Resistance to CDK4/6 inhibitors

Deciphering the connection of genetics, immune infiltration and prognosis